According to a press release, Proximo Medical has been announced as the commercial partner for Biotronik’s peripheral vascular intervention (PVI) platform in select US markets.
Proximo Medical is a fractional commercial organisation for start-up medical device technologies and established medical device companies looking to expand adoption on select products in the US market.
Biotronik’s PVI portfolio is designed for the treatment of peripheral artery disease and includes the Pulsar stent, which is the only 4-French (4F) self-expanding stent approved in the USA. Additional products include the Astron stent system, Passeo PTA balloon catheters and Fortress introducer sheaths.
“By partnering Biotronik’s solutions and innovations with Proximo, we accelerate our ability to help physicians deliver improved outcomes to patients,” states Ryan Walters, president, Biotronik. “At Biotronik, our focus is always on innovation that improves patient lives. We know millions of American’s suffer from peripheral artery disease and this partnership will help ensure this patient population has access to safe and effective treatment options.”
“I was an investigator in the trial of the Biotronik Pulsar stent,” states Craig Walker, president and medical director, Cardiovascular Institute of the South; clinical professor of Medicine, Tulane University and Louisiana State University Medical Schools; and chairman, New Cardiovascular Horizons. “I was impressed that this stent, which has a 4F delivery system, was easy to deploy accurately and had good clinical patency. I think this will be very helpful particularly in cases where standard 5F or 6F sheaths may be occlusive.”
